cover
Contact Name
Fajri Marindra S
Contact Email
fajrifkunri@gmail.com
Phone
+6285278154342
Journal Mail Official
actabioina@gmail.com
Editorial Address
Jl. Salemba Raya No 6, Jakarta 10430
Location
Kota adm. jakarta pusat,
Dki jakarta
INDONESIA
Acta Biochimica Indonesiana
ISSN : 26546108     EISSN : 26543222     DOI : https://doi.org/10.32889
Core Subject : Science,
Acta Biochimica Indonesiana (ActaBiolna) is a peer-reviewed and open-access journal that disseminates original research articles and review articles covering diverse topics in Biochemistry and Molecular Biology. The journal is published biannually by Indonesian Society for Biochemistry and Molecular Biology.
Articles 112 Documents
Association between vitamin D receptor FokI polymorphism and hypertension in Indonesian ischemic stroke patients: a cross-sectional study Arrizal, Rizki; Arina, Cut Aria; Siregar, Yahwardiah
Acta Biochimica Indonesiana Vol. 9 No. 1 (2026): Acta Biochimica Indonesiana
Publisher : Indonesian Society for Biochemistry and Molecular Biology

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32889/actabioina.237

Abstract

Background: Vitamin D receptor (VDR) FokI polymorphism (rs2228570) affects VDR protein transcriptional activity and may influence hypertension risk through renin-angiotensin system modulation. However, evidence in Southeast Asian stroke populations remains limited. Objective: To investigate the association between VDR FokI polymorphism and hypertension in Indonesian ischemic stroke patients. Methods: This cross-sectional study enrolled 85 ischemic stroke patients (50 hypertensive, 35 normotensive) from Medan, Indonesia. VDR FokI genotypes (CC, CT, TT) were determined using PCR-RFLP. Association with hypertension was analyzed using chi-square test. Results: Genotype distribution showed CC and CT at equal frequency (44.7% each) and TT at 10.6%, with corresponding C and T allele frequencies of 67.1% and 32.9%, respectively. Among hypertensive stroke patients, CT genotype predominated (52.0%), whereas CC genotype was most prevalent in normotensive patients (57.1%). Despite these distributional differences, no significant association was observed between VDR FokI polymorphism and hypertension (χ² = 3.732, p = 0.155). Conclusion: VDR FokI polymorphism was not significantly associated with hypertension in Indonesian ischemic stroke patients, suggesting that genetic predisposition via this single polymorphism may be overshadowed by established stroke pathophysiology or complex gene-environment interactions in this specific clinical context.
Efficacy of liposomal amphotericin B eye drops at two concentrations in experimental aspergillus keratomycosis in rabbits Amalia, Husnun; Ridwan, Rahmawati; Estuningtyas, Ari; Sitompul, Ratna; Adawiyah, Robiatul; Freisleben, Hans-Joachim
Acta Biochimica Indonesiana Vol. 9 No. 1 (2026): Acta Biochimica Indonesiana
Publisher : Indonesian Society for Biochemistry and Molecular Biology

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32889/actabioina.240

Abstract

Background: Keratomycosis, a fungal corneal infection prevalent in tropical regions, frequently leads to visual impairment and blindness. Liposomal amphotericin B (L-AmB) offers improved efficacy and reduced toxicity compared to conventional amphotericin B deoxycholate and represents a promising option for topical ophthalmic use. Objective: To evaluate and compare the therapeutic efficacy of L-AmB eye drops at 0.15% and 0.5% concentrations in experimental Aspergillus keratomycosis in New Zealand White rabbits. Methods: Four rabbits received midstromal corneal inoculation with a mixed suspension of Aspergillus flavus, A. fumigatus, A. niger, and A. terreus (2 x 10⁴ CFU/0.05 mL). L-AmB eye drops were applied hourly from day 8 post-inoculation until corneal cultures became negative. Antifungal susceptibility was assessed by disc diffusion. Clinical response was monitored by slit lamp examination using a modified scoring system. Results: Negative corneal cultures were achieved in all treated eyes within 10 to 18 days (mean 15 days, L-AmB 0.15%) and 11 to 15 days (mean 14 days, L-AmB 0.5%). No toxic effects were observed. Complete corneal transparency without cicatrix was achieved in one eye treated with L-AmB 0.15%. Conclusion: Both concentrations were effective and safe. Liposomal AmB 0.15% appears as efficacious as 0.5% for experimental Aspergillus keratomycosis. Clinical studies in humans are warranted.

Page 12 of 12 | Total Record : 112